Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ULTRAGENYX PHARMACEUTICAL INC.

(RARE)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/20/2021 09/21/2021 09/22/2021 09/23/2021 09/24/2021 Date
96.44(c) 96.06(c) 96.49(c) 97.5(c) 95.11(c) Last
400 088 302 266 335 133 403 015 232 860 Volume
-1.86% -0.39% +0.45% +1.05% -2.45% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 356 M - -
Net income 2021 -453 M - -
Net cash position 2021 606 M - -
P/E ratio 2021 -14,4x
Yield 2021 -
Sales 2022 409 M - -
Net income 2022 -394 M - -
Net cash position 2022 401 M - -
P/E ratio 2022 -17,1x
Yield 2022 -
Capitalization 6 452 M 6 452 M -
EV / Sales 2021 16,4x
EV / Sales 2022 14,8x
Nbr of Employees 893
Free-Float 95,7%
More Financials
Company
Ultragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.... 
More about the company
Ratings of Ultragenyx Pharmaceutical Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about ULTRAGENYX PHARMACEUTICAL INC.
09/09MEDIA ADVISORY : Ultragenyx Announces Mepsevii« (vestronidase alfa) Receives Reimbursement..
AQ
09/09Ultragenyx Pharmaceutical Inc. Announces Mepsevii« (Vestronidase Alfa) Receives Reimbur..
CI
09/07Ultragenyx to Present at Morgan Stanley Healthcare Conference
GL
09/07ULTRAGENYX PHARMACEUTICAL : Says Crysvita Wins Canada Approval for Second Indication for E..
MT
09/07MEDIA ADVISORY : Ultragenyx Canada Announces Health Canada Approval of a Second Indication..
AQ
09/07Ultragenyx Canada Announces Health Canada Approval of Second Indication for CrysvitaÖ (..
CI
09/02ULTRAGENYX PHARMACEUTICAL : to Participate in Panel at Citi's 16th Annual BioPharma Health..
AQ
09/01ULTRAGENYX PHARMACEUTICAL : to Participate in Panel at Citi's 16th Annual BioPharma Health..
AQ
08/23ULTRAGENYX PHARMACEUTICAL : Wins Brazilian Approval of Dojolvi for Treatment of Long-Chain..
MT
08/23Ultragenyx Announces Approval of Dojolvi« (triheptanoin) in Brazil for the Treatment of..
GL
08/23Ultragenyx Pharmaceutical Inc Announces Approval of Dojolvi« (triheptanoin) in Brazil f..
CI
08/19ULTRAGENYX PHARMACEUTICAL : UBS Starts Ultragenyx Pharmaceutical at Sell With $73 Price Ta..
MT
08/18ULTRAGENYX PHARMACEUTICAL : Reports Inducement Grant Under Nasdaq Listing Rule 5635(4)
AQ
08/17ULTRAGENYX PHARMACEUTICAL : Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
AQ
08/04Today on Wall Street: Is the economic recovery still on track?
More news
News in other languages on ULTRAGENYX PHARMACEUTICAL INC.
09/07Ultragenyx déclare que Crysvita obtient l'approbation du Canada pour une deuxième indic..
09/07NOTE AUX MÉDIAS : Ultragenyx Canada annonce l'approbation par Santé Canada d'une deuxième ..
08/04Hoy en Wall Street: ┐Sigue en marcha la recuperación económica?
More news
Analyst Recommendations on ULTRAGENYX PHARMACEUTICAL INC.
More recommendations
Stock Trading Strategies
ULTRAGENYX PHARMACEUTICAL INC. - 2020
The underlying trend is in force again
BUY
More Stock Trading Analysis
Chart ULTRAGENYX PHARMACEUTICAL INC.
Duration : Period :
Ultragenyx Pharmaceutical Inc. Technical Analysis Chart | RARE | US90400D1081 | MarketScreener
Technical analysis trends ULTRAGENYX PHARMACEUTICAL INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Last Close Price 95,11 $
Average target price 145,94 $
Spread / Average Target 53,4%
EPS Revisions
Managers and Directors
Emil D. Kakkis President, Chief Executive Officer & Director
Mardi C. Dier Chief Financial Officer & Executive Vice President
Daniel G. Welch Non-Executive Chairman
Dennis Karl Huang Chief Technical Operations Officer & Senior VP
Camille L. Bedrosian Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capi. (M$)
ULTRAGENYX PHARMACEUTICAL INC.-31.29%6 452
GILEAD SCIENCES, INC.22.19%89 259
BIONTECH SE309.08%80 542
WUXI APPTEC CO., LTD.34.39%68 685
REGENERON PHARMACEUTICALS32.25%66 425
VERTEX PHARMACEUTICALS-22.31%47 634